FBIO vs. XOMA, EBS, LXRX, CBIO, VNDA, CDXS, IRWD, SGMO, ACHV, and AGEN
Should you be buying Fortress Biotech stock or one of its competitors? The main competitors of Fortress Biotech include XOMA Royalty (XOMA), Emergent Biosolutions (EBS), Lexicon Pharmaceuticals (LXRX), Crescent Biopharma (CBIO), Vanda Pharmaceuticals (VNDA), Codexis (CDXS), Ironwood Pharmaceuticals (IRWD), Sangamo Therapeutics (SGMO), Achieve Life Sciences (ACHV), and Agenus (AGEN). These companies are all part of the "biotechnology" industry.
Fortress Biotech vs. Its Competitors
XOMA Royalty (NASDAQ:XOMA) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.
XOMA Royalty presently has a consensus target price of $69.50, indicating a potential upside of 85.73%. Fortress Biotech has a consensus target price of $16.50, indicating a potential upside of 324.16%. Given Fortress Biotech's higher probable upside, analysts plainly believe Fortress Biotech is more favorable than XOMA Royalty.
Fortress Biotech has a net margin of -24.84% compared to XOMA Royalty's net margin of -27.57%. XOMA Royalty's return on equity of 2.63% beat Fortress Biotech's return on equity.
XOMA Royalty has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500.
In the previous week, XOMA Royalty had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 4 mentions for XOMA Royalty and 2 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 1.53 beat XOMA Royalty's score of 1.23 indicating that Fortress Biotech is being referred to more favorably in the news media.
95.9% of XOMA Royalty shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 9.1% of XOMA Royalty shares are held by company insiders. Comparatively, 27.9% of Fortress Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
XOMA Royalty has higher earnings, but lower revenue than Fortress Biotech. XOMA Royalty is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.
Summary
Fortress Biotech beats XOMA Royalty on 9 of the 16 factors compared between the two stocks.
Get Fortress Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fortress Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:FBIO) was last updated on 9/14/2025 by MarketBeat.com Staff
Free FBIO Stock Alerts